Is there a role for atezolizumab as a first-line agent for metastatic urothelial carcinomas?
Based on the abstract from IMvigor 210 presented at ASCO this year, are you offering atezo to patients who otherwise may not tolerate platinum-based chemotherapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Washington School of Medicine
Answered on
The first question is whether the patient can tolerate cisplatin-based chemotherapy and whether or not they received (neoadjuvant or adjuvant) cisplatin-based chemotherapy within at least 1 year (if received peri-operative cisplatin-based therapy, it is a longer discussion regarding re-challenge tha...
Join for free or sign in to see the full answer